Tag: Hyperparathyroidism

Rocaltrol is a brand name for calcitriol, the most potent and active form of vitamin D, which plays a crucial role in regulating calcium and phosphate in the body. It is primarily used to manage conditions resulting from a body’s inability to produce sufficient active vitamin D, often due to chronic kidney disease or parathyroid disorders.

The U.S. Food and Drug Administration (FDA) first approved generic versions of cinacalcet on March 8, 2018. This milestone introduced competition for the brand-name drug Sensipar, which had sales of $1.72 billion in 2017. The question of *when did cinacalcet go generic?* is pivotal for understanding patient access and cost.

For many patients, cinacalcet is an effective treatment for hyperparathyroidism, but clinical studies and anecdotal reports show a significant incidence of gastrointestinal side effects, prompting the need for alternatives. Understanding the available treatment options is crucial for achieving optimal management of the condition, especially in those with chronic kidney disease (CKD).

In 2004, cinacalcet was approved by the FDA as the first agent in its class, definitively answering the question, 'What category is cinacalcet?' and ushering in a new treatment option for hyperparathyroidism. This medication is classified as a calcimimetic agent and is used to manage specific conditions involving overactive parathyroid glands.

Between 25% and 66% of patients taking cinacalcet report significant gastrointestinal side effects, such as nausea and vomiting, leading many to seek alternative treatments. Deciding what can be used instead of cinacalcet is a complex process that depends on the specific type of hyperparathyroidism, patient tolerance, and other co-existing medical conditions.

For many patients with chronic conditions such as secondary hyperparathyroidism or certain forms of parathyroid cancer, cinacalcet therapy is a long-term or even lifelong commitment. The precise length of time for how long can you take cinacalcet for is highly dependent on the underlying condition, the patient's individual response to treatment, and consistent medical supervision.

Cinacalcet is a prescription-only medication, approved by the FDA for treating serious conditions related to parathyroid hormone imbalances. This strict classification is why you cannot **buy cinacalcet over the counter**, as its use requires careful medical oversight to manage efficacy and potential side effects.

Cinacalcet (brand name Sensipar) is a calcimimetic agent that works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands to extracellular calcium. It is an important medication for controlling high parathyroid hormone (PTH) levels, and the generic version offers a potentially more affordable option for many patients.

A 2024 meta-analysis revealed that the global prevalence of secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is approximately 49.5% [1.7.1, 1.7.2]. A key medication to manage this is cinacalcet, but what's another name for cinacalcet? The most common brand name is Sensipar [1.2.1].

A 2020 meta-analysis involving over 110,000 hemodialysis patients found that treatment with Zemplar (paricalcitol) was associated with better overall survival compared to other vitamin D receptor activators. This vital medication, a synthetic form of vitamin D, raises the question: **What is another name for Zemplar?** The answer lies in its generic name, paricalcitol, which is essential knowledge for patients and healthcare providers.